Chimerix to Present at Cowen and Company 42nd Annual Health Care Conference
DURHAM, N.C., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX) announced that CEO Mike Sherman and CFO Mike Andriole will participate in a fireside chat at the Cowen and Company 42nd Annual Health Care Conference on March 7, 2022, at 12:50 p.m. ET. An audio webcast will be available on Chimerix's Investor Relations website and archived for 90 days. Chimerix focuses on developing medicines to improve the lives of patients with severe diseases, including the recently FDA-approved TEMBEXA® for smallpox and promising therapies for acute myeloid leukemia and glioma.
- None.
- None.
DURHAM, N.C., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced that Mike Sherman, Chief Executive Officer and Mike Andriole, Chief Financial and Business Officer, will participate in a fireside chat at the Cowen and Company 42nd Annual Health Care Conference on Monday, March 7, 2022 at 12:50 p.m. ET.
An audio webcast of the fireside chat will be available on the Investor Relations section of Chimerix's website at ir.chimerix.com, where it will be archived for approximately 90 days.
About Chimerix
Chimerix is a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. In June 2021, the U.S. Food and Drug Administration granted approval of TEMBEXA® for the treatment of smallpox as a medical countermeasure. The Company has two other advanced clinical-stage development programs, ONC201 and dociparstat sodium (DSTAT). ONC201 is in development for recurrent H3 K27M-mutant glioma as its lead indication. DSTAT is in development as a potential first-line therapy in acute myeloid leukemia.
CONTACT:
Investor Relations:
Michelle LaSpaluto
919 972-7115
ir@chimerix.com
Will O’Connor
Stern Investor Relations
212-362-1200
will@sternir.com
FAQ
What event will Chimerix participate in on March 7, 2022?
Who are the executives representing Chimerix at the conference?
Where can I watch the Chimerix conference fireside chat?
What is the recent FDA approval related to Chimerix?
What are the clinical-stage programs Chimerix is developing?
